Open Access Open Access  Restricted Access Subscription or Fee Access

Isoquercetin in Bladder Cancer: a Perspective of Current Potential Uses in Clinical Practice and Future Directions in Clinical Research

(*) Corresponding author

Authors' affiliations



Isoquercetin is a biologically active, naturally occurring flavonol, with multiple potential clinical applications against bladder cancer. Isoquercetin can be administered both as a supplement and as an active pharmacological principle, and exerts potent antioxidant, anti-thrombotic, anti-inflammatory as well as anti-proliferative effects in vivo. As a supplement, isoquercetin may be consumed for prevention of bladder cancer recurrence in high- risk patients. As a drug, isoquercetin has shown promising activity as an anti-thrombotic and as an anti-fatigue agent in cancer patients, and it may be of use in patients with metastatic bladder cancer. Finally, isoquercetin may enhance BCG efficacy in patients with localized cancer undergoing intravesical adjuvant therapy. In conclusion, isoquercetin represents an attractive nutritional and pharmacological agent for the management of bladder cancer. Further epidemiological studies and clinical trials are warranted.
Copyright © 2019 Praise Worthy Prize - All rights reserved.


Bladder Cancer; Cancer-Related Fatigue; Flavonoids; Isoquercetin; Quercetin

Full Text:



D. Aune et al., Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-A systematic review and dose-response meta-analysis of prospective studies, Int. J. Epidemiol., Volume 46, (Issue 3), June 2017, Pages 1029-1056.

C. S. Patil, V. P. Singh, P. S. V. Satyanarayan, N. K. Jain, A. Singh, and S. K. Kulkarni, Protective effect of flavonoids against aging- and lipopolysaccharide-induced cognitive impairment in mice, Pharmacology, Volume 69, (Issue 2), October 2003, Pages 59-67.

A. N. Panche, A. D. Diwan, and S. R. Chandra, Flavonoids: An overview, Journal of Nutritional Science, Volume 29, (Issue 47), December 2016.

G. Raman et al., Dietary intakes of flavan-3-ols and cardiometabolic health: Systematic review and meta-analysis of randomized trials and prospective cohort studies, Am. J. Clin. Nutr. Volume 110, (Issue 5), November. 2019, Pages 1067-1078.

H. Xu, J. Luo, J. Huang, and Q. Wen, Flavonoids intake and risk of type 2 diabetes mellitus: A meta-analysis of prospective cohort studies, Medicine (Baltimore), Volume 97, (Issue 19), May 2018.

G. Grosso et al., A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: Level of evidence and limitations, Mol. Nutr. Food Res., Volume 61, (Issue 4), April 2017.

R. Zamora-Ros et al., Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, Br. J. Cancer, Volume 111, (Issue 9), October 2014, Pages 1870-1880.

A. W. Boots, G. R. M. M. Haenen, and A. Bast, Health effects of quercetin: From antioxidant to nutraceutical, Eur. J. Pharmacol., Volume 585, (Issue 2-3), Pages 325-337.

J. Kühnau, The flavonoids. A class of semi-essential food components: their role in human nutrition., World. Rev. Nutr. Diet. Volume 24, June 1976, Pages 117-191.

K. Valentová, J. Vrba, M. Bancířová, J. Ulrichová, and V. Křen, Isoquercitrin: Pharmacology, toxicology, and metabolism, Food Chem. Toxicol., Volume 68, June 2014, Pages 267-282.

P. Ader, A. Wessmann, and S. Wolffram, Bioavailability and metabolism of the flavonol quercetin in the pig, Free Radic. Biol. Med., Volume 28, (Issue 7), April 2000, Pages 1056-1067.

J. I. Zwicker et al., Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve[hypercoagulability in advanced cancer, JCI insight, Volume 4, (Issue 4), February 2019.

I. Erlund et al., Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers, Eur. J. Clin. Pharmacol., November 2000, Volume 56, (Issue8), Pages 545-553.

C. Buonerba et al., Isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib (QUASAR): Results of a phase I trial, Front. Pharmacol., Volume 9, (Issue 189), March 2018.

L. Jia, S. Huang, X. Yin, Y. Zan, Y. Guo, and L. Han, Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction, Life Sci., September 2018 Volume 1; (Issue 208), Pages 123-130.

J. Lu et al., Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity, J. Pathol., Volume 222, (Issue 2), October 2010; Pages 199-212

R. A. Rafiq, A. Quadri, L. A. Nazir, K. Peerzada, B. A. Ganai, and S. A. Tasduq, A Potent Inhibitor of Phosphoinositide 3-Kinase (PI3K) and Mitogen Activated Protein (MAP) Kinase Signalling, Quercetin (3, 3’, 4’, 5, 7-Pentahydroxyflavone) Promotes Cell Death in Ultraviolet (UV)-B-Irradiated B16F10 Melanoma Cells, PLoS One, Volume 10 (Issue 7), July 2015.

F. Chen et al., Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways, Oncol. Rep., Volume 36, (Issue 1), June 2016, Pages 165–172.

G. Di Lorenzo et al., Complete response and fatigue improvement with the combined use of cyclophosphamide and quercetin in a patient with metastatic bladder cancer a case report, Medicine (Baltimore), Volume 95, (Issue 5), February 2016.

A. R. Zlotta, N. E. Fleshner, and M. A. Jewett, The management of BCG failure in non-muscle-invasive bladder cancer: An update, Can. Urol. Assoc. J., Volume 3, (Issue 6), December 2009, Pages 199-205.

A. Agarwal, U. Agrawal, S. Verma, N. K. Mohanty, and S. Saxena, Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre-and post-intravesical combination immunotherapy, Immunopharmacol. Immunotoxicol., Volume 32, (Issue 2), June 2010, Pages 348-56.

R. Pichler et al., Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer, Cancer Immunol. Immunother., Volume 66, (Issue 4), December 2016, Pages 427–440.

J. Mlcek, T. Jurikova, S. Skrovankova, and J. Sochor, Quercetin and its anti-allergic immune response, Molecules, Volume 21, (Issue 5), May 2016, Page 623.

Hajime Karasuyama, Kensuke Miyake, Soichiro Yoshikawa, Yohei Kawano, Yoshinori Yamanishi, How do basophils contribute to Th2 cell differentiation and allergic responses?, International Immunology, Volume 30, Issue 9, September 2018, Pages 391–396.


M. Ferro et al., Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor, World J. Urol., 2020 January; Volume 38, (Issue1): Pages 143-150.

D. Kempuraj et al., Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells, Br. J. Pharmacol., 2005. August 2005, Volume 145, (Issue 7), Pages 934–944.

E. Eriksson, I. Milenova, J. Wenthe, R. Moreno, R. Alemany, and A. Loskog, IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1, J. Immunol., Volume 202, (Issue 3) February 2019, Pages 787-798.

P. Ghatalia, M. Zibelman, D. M. Geynisman, and E. Plimack, Approved checkpoint inhibitors in bladder cancer: which drug should be used when?, Ther. Adv. Med. Oncol. Volume 30, July 2018.

Please send any question about this web site to
Copyright © 2005-2024 Praise Worthy Prize